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ABSTRACT
Background: In the United States Hepatitis C virus (HCV) viral clearance is 
estimated to range between 20% and 30%.  The objective of this study was 
to estimate the frequency of HCV clearance and identify correlates of  viral 
clearance among patients newly identified as HCV antibody positive in a 
large urban health system in Los Angeles, California.
Methods: We identified patients between November 2015 and September 
2017 as part of a newly implemented HCV screening and linkage-to-care 
program at University of California Los Angeles (UCLA) Health System. All 
patients were eligible for screening, though there were additional efforts to 
screen patients born between 1945 and 1965. We reviewed Medical records 
to categorize anti-HCV antibody positive patients as having spontaneously 
cleared HCV infection (HCV RNA not detected) or not (HCV RNA detected). 
We excluded those with a prior history of anti-HCV positivity or history of 
HCV treatment. We compared differences between those with and without 
detectable HCV RNA using chi-square test, Fisher’s exact test, and t-test as 
appropriate. We assessed factors associated with HCV clearance using 
logistic regression analysis. 
Results: Among the 320 patients included in this study, 56% were male. 
Baby boomers (52-72 years of age) comprised the single largest age group 
(62%).  We found spontaneous HCV clearance in 58% (n=185).  HCV viral 
clearance was slightly higher among women as compared to men (63% vs. 
53%; p value=0.07) and varied by race/ethnicity: clearance among 
Blacks/African Americans was 37% vs. 58% among whites (p value=0.02). 
After adjusting for age, race/ethnicity, and sex we found that those 
diagnosed with chronic kidney disease had a tendency of decreased HCV 
viral clearance (adjusted OR=0.34; 95% CI 0.14-1.03). 
Conclusion: Of those patients newly identified as anti-HCV positive, 58% 
had cleared HCV virus, while the rest showed evidence of active infection. In 
addition, we found that clearance varied by race/ethnicity and clinical 
characteristics. 
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Background 
 In the United States the proportion of those with spontaneous 
hepatitis C virus (HCV) clearance varies between studies.  Historically it’s 
been estimated that clearance occurs in 15% -20% of patients infected with 
HCV [1]. Recent data suggest that spontaneous clearance of HCV infection in
the absence of treatment is higher than previously estimated [1-3].  In one of
the first studies to estimate spontaneous HCV clearance –defined on the 
basis of HCV RNA assessments within 24 months of diagnosis – the frequency
of clearance was 26% [4]..  
Why certain groups clear HCV infection without antiviral treatment 
remains unclear [5-8].  Studies suggest host innate immune system or 
genetic factors may play a role [9-11]. Factors such as sex, race/ethnicity, 
young age, HLA type, IL28B genotype, HIV-infection status, and chronic 
hepatitis B infection are known to affect clearance [2, 4, 10, 12-21]. 
However, most studies on spontaneous HCV viral clearance are limited by 
small sample size, heterogeneous definitions of cases, and study inclusion 
criteria, including study populations that are limited to high-risk groups such 
as illicit substance users and men who have sex with men [4, 7, 12, 13]. 
Little is known about screening populations, in particular baby boomers, a 
birth cohort known to have increased risk of HCV infection [22-25]. Our aim 
was to identify the frequency of and factors associated with spontaneous 
HCV clearance among patients participating in a hepatitis C screening 
program at a large urban health system in Los Angeles, California.
Methods
Study population
Patients seeking primary care services at UCLA Health were screened for 
HCV infection between November 2015 and September 2017.  As per the US 
preventive task force recommendations for HCV screening, testing was 
initiated with the HCV antibody test (anti HCV Ab) and was targeted to high 
risk groups, as well as one-time testing of adults born between 1945 and 
1965 regardless (regardless of their HCV risk factors)[26]{al, 2013 #517}. 
The program has been previously described [27]. Briefly, a structural 
intervention using electronic medical record prompts was implemented to 
promote HCV screening among patients seeking care at UCLA health. The 
electronic medical record (EMR) prompts were specifically developed to not 
only capture high risk groups for HCV infection, who had never tested for 
HCV, but also to target screening towards “baby boomers” (i.e., those born 
between 1945 and 1965) without any prior history of HCV testing. 
In this study, we reviewed the medical records of patients who were HCV 
antibody positive during the screening period (“newly identified cases”). We 
also conducted interviews to confirm history of treatment or testing history 
for HCV. Patients who reported that they were under treatment or had 
received treatment for HCV in the past were excluded from this study. 
Patients who reported positive HCV antibody or RNA test results before the 
screening period were also excluded.
Measures
HCV antibody testing was conducted by the UCLA microbiology laboratory, 
using standard protocols for the ADVIA Centaur XP System (Siemens Medical 
Solutions USA, Inc., Malven, PA).  The ADVIA Centaur HCV assay is an in vitro 
diagnostic immunoassay for the qualitative determination of immunoglobulin
G (IgG) antibodies to hepatitis C virus in human serum and plasma using the 
ADVIA Centaur® System.  The assay was used in conjunction with HCV RNA 
testing to determine HCV infection status.  Specifically, HCV antibody 
reactive tests were tested for HCV RNA viral load using the COBAS® 
Ampliprep/ COBAS® TaqMan® HCV test (Qualitative and Quantitative, v2.0; 
Pleasanton, California).  We collected patient demographic and clinical 
characteristics including age, sex, race/ethnicity, and laboratory values 
including liver function tests (aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), platelet count, bilirubin levels) and, human 
immunodeficiency virus (HIV) infection status.  In cases where these 
laboratory tests were not conducted on the same day as the HCV testing, we 
matched the laboratory testing data to the HCV testing data such that only 
testing data within 3 months of HCV antibody screening was included.  We 
used ICD-10 codes (ICD-10 code for CKD: ICD-10-CM: N18* and ICD-10 code 
for DM: E11* and E10*) to determine whether patients were diagnosed with 
chronic kidney disease (CKD) or diabetes mellitus. These clinical markers 
were included in the study given the scientific literature indicating the 
association between CKD, diabetes, and chronic HCV infection [28-31]
{Kusnir, 2016 #438}
Statistical Analysis
We defined HCV clearance as evidence of HCV Ab reactivity and HCV RNA 
non-detectable test results in the absence of treatment. We examined 
differences between those who cleared their HCV infection and those who 
remained chronically infected using chi-square test, Fisher’s exact test, and 
t-tests.  We used logistic regression analysis to examine factors associated 
with HCV clearance including sociodemographic and clinical characteristics.  
We conducted all analyses using SAS 9.4 (NC, USA). 
Human subjects
The UCLA Institutional Review Board (IRB) approved the study activities 
(IRB# 15-001226). 
Results
Study population characteristics.  
Three hundred and eighty-six patients were considered newly identified HCV 
Ab Positive. Among this group, 135 patients had detectable HCV RNA 
indicating current active infection.  Of the 251 HCV antibody positive/HCV 
RNA undetectable patients, four had a false positive anti-HCV antibody test 
result, ten had a prior history of successful HCV treatment with clearance of 
HCV infection due to treatment (i.e., not spontaneous clearance), and 52 
could not be reached for verification of their prior history of HCV treatment 
(Figure 1).  These 66 patients were excluded from the study resulting in a 
total of 320 study patients – 135 HCV antibody positive/HCV RNA positive 
(i.e., infection not cleared) and 185 HCV antibody positive/ HCV RNA 
negative (i.e., spontaneous clearance).  The majority of the study population 
was born between 1945 and 1965 (62%) and 56% were male. 
Whites/Caucasians represented the single largest race/ethnicity group (64%),
followed by Black/African American (13%) and Hispanic/Latino (9%) (Table 
1). Among our study population of newly identified HCV antibody positive 
patients participating in a HCV screening program 58% spontaneously 
cleared HCV. 
Prevalence of HCV clearance
The prevalence of HCV clearance varied by a number of demographic and 
clinical characteristics with HCV clearance being somewhat higher among 
women (63% vs. 53%; p value=0.07), although not meeting statistical 
significance, and varying by race/ethnicity (Table 2).  Specifically, we note 
that HCV clearance was lowest among those who identified as Black/African 
American (37%).  
Factors associated with spontaneous HCV clearance
After adjusting for age and sex, we found that race/ethnicity was 
independently associated with spontaneous HCV clearance.  Those who 
identified as African American/Black had a 57% decreased odds of HCV 
clearance as compared to Whites [adjusted odds ratio (aOR) =0.43; 95% 
confidence interval (CI) =0.21-0.92) (Table 2).  Moreover, those diagnosed 
with chronic kidney disease (aOR=0.34; 95% CI 0.14-1.03) had a tendency to
decreased likelihood of spontaneous HCV clearance. 
Discussion 
We investigated the frequency of and factors associated with spontaneous 
HCV viral clearance among patients participating in a hepatitis C screening 
program at a large urban health system in Los Angeles. In this study, 58% of 
patients with newly identified infection had evidence of HCV viral clearance. 
It should be noted that we only included newly identified HCV Ab positive 
patients with prior testing and verified treatment history through both chart 
review and patient interviews, which may explain the difference compared to
other published studies [1, 4, 30].  Among our patient population, 
spontaneous HCV viral clearance varied by race/ethnicity and was somewhat
less likely to occur among those with chronic kidney disease (CKD).
Consistent with previous studies, clearance was greater among white 
patients compared to their black counterparts [1, 4]. Previous studies on 
genetic markers perhaps could explain the increased proportion of 
spontaneous viral clearance among non-black patients [10, 32-34]. Key 
modification with natural killer (NK) cells populations, HLA class II alleles and 
IL28B polymorphism have been suggested to predict the relationship 
between ethnic characteristics and HCV clearance [1, 32, 35-37]. A study 
conducted by Golden-Mason et al proposed that the proportion of NKp46 
expression was lower among African Americans compared to their white 
counterparts [1, 35]. NK cells are known to be the immune system’s first line 
of defense against viral pathogens [38]. NK cells do this work by eliminating 
virus-infected cells directly via cytolytic mechanisms or indirectly by 
secreting cytokines [38, 39].  Moreover, HLA type II alleles have been 
suggested to have some conflicting roles however, research suggests their 
role with HCV clearance includes the fact that African Americans have 
weaker HCV specific immunity [37]. Furthermore, IL28B polymorphism is 
known to be the strongest host gene predictor of HCV clearance. Previous 
studies discuss that IL28B allele rs12979860 were less likely to be observed 
among persons of African descent compared to European descent. Study by 
Ge et al, outlines the fact that HCV clearance occurred in 36.4% among non-
blacks compared to 9.3% among black persons [10]. The suggested 
mechanism along with previous studies provides some evidence that NK cells
and other genetic markers can play a protective role in patients exposed to 
hepatitis C. However, despite studies on predictors of HCV clearance, the 
association between ethnic characteristics and HCV viral clearance is not 
well understood and should be explored further. 
Our study also found that patients with chronic kidney disease were 
somewhat less likely to clear HCV infection compared to those without 
chronic kidney disease. Due to several clinical implications, in 2017, the 
Kidney Disease Improving Global Outcome organization drafted specific 
guidelines to increase HCV screening among  chronic kidney disease patients
[40]. Earlier studies propose that HCV infection may influence the 
development of chronic kidney disease by stimulating a series of immune 
reactions that targets the kidney, which ultimately leads to 
glomerulonephritis [29, 41]. According to Azmi et al, the mechanism related 
to glomerulonephritis and HCV infection is known to be immune-complex 
mediated. Researchers believe that deposition of the immune complexes can
trigger glomerulonephritis[41]. Overall, we also observed that HCV was 
associated with chronic kidney disease, although from our cross-sectional 
study we cannot determine causation. 
There are a number of limitations in our study including: (1) our 
modest sample size limits our ability for extensive analyses; (2) given the 
lack of information on the precise timing of HCV exposure and HCV infection 
we are unable to determine time to HCV clearance; (3) exclusion of patients 
whose HCV clearance status could not be verified could have biased our 
estimates of HCV clearance; (4) lack of information on viral subtype limited 
our ability to determine whether HCV subtype is associated with clearance; 
and (5) we included only “newly identified cases” of HCV, excluding patients 
with previous HCV positive results, thus our results are not generalizable to 
other populations nor do they represent an unbiased population estimate of 
HCV clearance. Finally, we were unable to verify a specific Race/Ethnicity for 
patients included in the “Other” category during data extraction, which could
have potentially affected our conclusions on the associations between HCV 
clearance and Race/ethnicity. Despite those limitations, this is one of a few 
studies exploring difference in HCV spontaneous clearance among a 
screening population, with rigorous strategies employed to exclude those 
with previous treatment history or false positive testing status.
Future studies should explore on the social regulation of gene 
expression. According to Cole et al, social regulation of gene expression is a 
conceptual relationship between genes and social world[42].  Recent studies 
suggest clear associations between social factors and the regulations of the 
human genome [42-44]. Perhaps the decreased expression of NKp46 or 
other genetic factors observed among black patients can be attributed to 
their exposure to poor environmental, social and economic conditions. 
Asking and attempting to answer those questions might enable a better 
understanding of what drives genetic differences at the molecular level.
Conclusions
Overall, this study confirms a higher frequency of HCV spontaneous 
clearance. In addition, this study identified certain subgroups more likely to 
clear HCV infection. Individuals who are at greater risk for HCV infection such
as those who identify as African American and patients with chronic kidney 
disease should be prioritized for HCV screening and treatment initiatives. 
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Table 1. Demographic and clinical characteristics of newly
identified HCV
antibody positive patients, UCLA Health system, 
November 2015-September 2017
 
 
HCV
Antibody
Positive~
(n=320)
  n %
Age group (years)
 18-52 99 31.4
 52-72 ("Baby Boomers") 198 61.5
 ≥73 23 7.1
Sex
 Male 179 55.9
 Female 140 44.1
Race/Ethnicity 
 Asian or Pacific Islander 5 1.8
 Black or African American 38 13.4
 Hispanic or Latino 25 8.8
 Other† 33 11.6
 White or Caucasian 183 64.4
Clinical Characteristics
Hepatitis C RNA detected 135 42
HIV Positive 10 3.1
Chronic Kidney Disease** 23 7.2
Diabetes Mellitus 45 14.2
Laboratory Results^
 ALT (U/L) 25 (17-47)
 AST(U/L) 26 (20-39)
 Platelet count
232 (188-
271)
 Bilirubin (mg/dL) 0.5 (0.3-0.7)
Abbreviations.  ALT=Alanine Transaminase; AST=Aspartate 
Transaminase, 
~Sum may not equal total because of missing 
information
†: includes participants self-identifying as multiracial
**CKD based on ICD-10 codes
^data presented as median and interquartile range
 
Table 2. Prevalence and factors associated with absence of HCV RNA among 
newly identified
 HCV antibody positive patients, UCLA Health system, 
November 2015-2017 
 
HCV RNA
negative 
P
value  
Unadjusted OR
(95% Cl)
Adjusted OR
(95% CI)
n %        
Total 185 58.0 -- -- --
Age group (years) 0.17
 18-52 58 58.6 Ref Ref
 52-72 ("Baby 
Boomers") 118 59.6
1.04 (0.64 -
1.70)
1.35 (0.75 -
2.39)
 ≥73 9 39.1 0.45 (0.18 -1.15)
0.45 (0.16 -
1.30)
Sex 0.07
 Male 95 53.1 Ref Ref
 Female 88 63.3 1.53 (0.97-2.40) 1.53 (0.91 -2.56)
Race/Ethnicity 0.02
 Asian 3 60.0 1.08 (0.18 -6.59)
1.00 (0.14 -
5.44)
 Black or African 
American 14 36.8
0.42 (0.21 -
0.86)
0.43 (0.21 -
0.92)
 Hispanic or Latino 10 40.0 0.48 (0.20 -1.12)
0.63 (0.26 -
1.57)
 Other† 27 82.0 3.87 (1.43 -10.51)
4.38 (1.54 -
12.44)
 White or Caucasian 106 58.2 Ref Ref
Clinical 
Characteristics
HIV Positive 0.33
 Yes 4 40.0 0.48 (0.13 –1.73) --
 No 180 58.3 Ref
Chronic Kidney 
Disease**
0.06
 Yes 9 39.1 0.45 (0.19 -1.06)
0.37 (0.14 -
1.03)
 No 173 59.0 Ref Ref
Diabetes Mellitus 0.76
 Yes 25 55.6 0.91 (0.48 -1.71) --
 No 157 57.9 Ref
             
Abbreviations.  OR=odds ratio; CI=confidence interval 
†: includes participants self-identifying as multiracial
**CKD based on ICD-10 codes 
Figure 1 HCV viral clearance population breakdown
